Australian native fungi spring to life during colder, wetter months
It is a mysterious world of colourful toadstools right out of a fairy tale, of bizarre white "cages" that smell of death and decay and of ghostly mushrooms that glow eerily in the dark.
Australia's native macrofungi — those visible fungus forms that can be seen with the naked eye and often appear during the coldest, darkest time of the year — play an essential role within any ecosystem.
They are nature's recyclers, fertilisers and rehabilitators.
While a few notorious introduced varieties have engendered a toxic reputation, Australia's native macrofungi remain largely an enigma.
Fewer than 10 per cent of the potentially hundreds of thousands of fungus species in Australia (estimates range up to 250,000) have been formally identified and described.
"It shows how little we know," ecologist and author Alison Pouliot said.
"There are whole lot of reasons for that. I think the big thing, for a lot of them, is they are out of sight, out of mind.
"They are most often underground for most of the year."
Fungi occupy a strange space somewhere between the animal and vegetable kingdoms, having some traits of each but being truly neither.
"They are a whole separate kingdom," Dr Pouliot explained.
Dr Pouliot said fungi get their nutrition through digestion like animals rather than from sunlight like plants.
"Fungi don't photosynthesise like plants," she said.
"They digest like we do.
"They are also made of a compound called chitin instead of cellulose like a plant. We find that in the animal kingdom. That's what a crayfish's shell is made of, for example."
The most visible component of macrofungi, such as the parasol-shaped mushroom, makes up a mere fraction of the living thing itself.
It is, in fact, the sex organ of a much larger organism that is most often hidden underground.
"Collectively we call them [the visible component] the reproductive sporing bodies," Dr Pouliot said
"A mushroom is just one type of structure. There are puffballs and morels, for example, and these are not mushrooms."
The greater part of the organism below the surface is called a "mycelium", which includes the seldom seen root structure.
A mycelium can range in size from mere specks to metres.
Some are among the largest living things on the planet, stretching square kilometres.
Many of the most familiar varieties become active in autumn, activated by changes in the soil.
"Why we see [them] most in autumn is the mycelium responds to a drop in soil temperature and an increase in soil moisture," Dr Pouliot explained.
A warmer, drier summer across south-eastern Australia has likely had an impact on how many native mushrooms and other macrofungi are able to be seen this year, according to Victorian Western District field naturalist Helen Langley.
"A few are appearing now in the Western District," Ms Langley said.
"There does appear to be less of them because it has been so dry.
"It has also got cold quickly this year, which hasn't helped."
Dr Pouliot said fungi were resilient, however, and should bounce back if and when the rain returned next year.
News stories about toxic mushrooms have blurred the terms "mushroom" and "toadstool".
Scientifically, at least, they are all now referred to as mushrooms.
"Originally a mushroom was an umbrella-shaped fungus that was edible, and a toadstool was an umbrella-shaped fungus that was toxic," Dr Pouliot explained.
"Over the years, those two terms have been used synonymously, and we saw books being published about things like poisonous mushrooms. The world was like, 'Hang on a minute. They're supposed to be edible'.
"Today, the word 'toadstool' has pretty much fallen out of use. It's more a poetic or literary term.
"And today the word mushroom doesn't refer to edibility, it just means umbrella-shaped."
The term "toadstool" (a stool for toads in English) has an etymology rooted in its toxicity, however.
"Tod" is the German word for "death", while "stuhl" is German for "chair".
A "bolete", meanwhile, is mushroom-shaped macrofungus that has a spongy underside with pores rather than the gills synonymous with mushrooms.
Ms Langley said people should avoid foraging for native fungi.
"Like many native plants, native mushrooms are not supposed to be picked and collected," she said.
"They are meant to be left alone in their natural environment.
"For a lot of native fungi, we just don't know about their toxicity. It is not worth the risk.
"My advice is not to touch them and just to look at them and enjoy them for what they are."
Several of the most recognisable macrofungi, including the charismatic fly amanita (Amanita muscaria), the infamous death cap mushroom (Amanita phalloides) and familiar edible varieties such as the common mushroom (Agaricus bisporus), are not native to Australia.
Dr Pouliot encouraged bush explorers to find and photograph Australia's fantastic and fabulous native fungi but suggested we don't disturb them and leave them be.
She said, among the potentially hundreds of thousands of species that could be discovered in Australian forests, were these spectacular varieties:
The striking rhubarb bolete (Boletellus obscurecoccineus) is distinctive for its red-to-rhubarb-coloured cap and underbelly of yellow pores. It's found among eucalypt leaf litter in Victoria, Tasmania, south-western WA and south-east NSW.
The widespread pretty horn (Calocera sinensis – calo = beautiful and cera = horn in Greek) appears as little yellow clubs or spikes. It's a wood-recycling fungus that grows on logs, branches and twigs.
Growing in south-eastern Australia, the green skinhead (Cortinarius austrovenetus) is unusual for its green colouration. Members of the genus Cortinarius are known as webcaps as they have a cortina, or web-like veil that protects the gills during early growth stages.
Appearing like rubies among the leaf litter on the forest floor, the tiny but conspicuous ruby bonnet (Cruentomycena viscidocruenta) is always a joy to find. It grows in wetter forests in Australia and New Zealand.
This fungus is not your average umbrella-shaped mushroom. The smooth cage fungus (Ileodictyon gracile), while striking to look at, has a fetid odour that is likely to repel you. Native to Australia, it often pops up in garden beds.
The gem-studded puffball (Lycoperdon perlatum) is a cosmopolitan species with many common names including warted puffball, common puffball and devil's snuff-box. You'll find it in all kinds of habitats from forests and woodlands to grass clearings, gardens and track edges.
The Australian parasol (Macrolepiota clelandii) often appears in grassy verges along roadsides. This handsome species is recognisable for its raised central brown knob, or umbo, and "chocolate-chip" scales. It's also known as the graceful parasol or slender parasol.
The endearing pixie's parasol (Mycena interrupta) has a Gondwanan distribution but here in Australia you'll find it in Tasmania, Victoria, NSW, South Australia and if you're really lucky, in Queensland.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
an hour ago
- News.com.au
Dr Boreham's Crucible: Oncology-focused Qbiotics hopes to crawl through IPO ‘window of opportunity'
Like other IPO candidates – and the list is growing – private oncology drug developer Qbiotics has been closely watching the trajectory of Virgin Australia since the airlines June 24 ASX listing. The biggest float since fast food chain Guzman y Gomez spiced up things in June last year, Virgin's initial public offer (IPO) has been seen as a barometer of broader investor appetite for new offerings. With Virgin shares holding nicely at cruising altitude, is it time for the Brisbane-based Qbiotics to debut? Qbiotics chief Stephen Doyle says IPO timing has never been right in the past, but the company now is positioned to crawl through the window of opportunity when it opens. In March the company appointed Jeffries and Bell Potter as joint lead managers for the putative float, and it is getting its financial reporting into shape. 'We have done the due diligence and prospectus drafting … all the things you need to do for an IPO,' Doyle says. 'At the end of the day it's picking the right time with the right catalysts to create value for shareholders.' Tapping nature's pharmacy The company may have found such a catalyst, having last month reported encouraging results from its phase II soft tissue sarcoma (STS) trial. The study road tests Qbiotics tigilanol tiglate (EBC-46), which derived from the depths of the Daintree rainforest. The company says tigilanol tiglate has a 'multi-factorial mode of action', including activating the protein kinase C. This leads to the disruption of the tumour's blood supply, while also stimulating a local inflammatory response. Separate from this, tigilanol tiglate can directly kill cancer cells within the tumour, in a way that promotes the development of anti-tumour immunity. This is like how a vaccine works. Qbiotics has phase II programs for both soft tissue sarcoma and head and neck cancers (HNCs). It also has less advanced programs in venous leg ulcers and anti-microbial and anti-inflammatory applications. Dogged effort wins canine approval Qbiotics has an approved product, Stelfonta, to treat canine mast cell tumours. The current standard of care is surgery - but anaesthesia is dangerous for older dogs and brachycephalic breeds (short snouted ones such as bulldogs, boxers, pugs and shih tzus). Stelfonta is administered by injection directly into the tumour mass. The European Medicines Agency approved Stelfonta in January 2020, followed by the US Food and Drug Administration in November 2020 and the Australian Pesticides and Veterinary Medicines Authority in July 2021. Stelfonta is distributed by the French group Virbac, which is responsible for all sales and marketing, while Qbiotics provides the finished product at a suitable margin. Doyle says the veterinary drug showed Qbiotics could take a product all the way from discovery to commercialisation. 'It was also a derisking strategy,' he says. 'The canine is a good surrogate for the human setting and that has been the case. 'We have some good safety and efficacy data in well over 20,000 dogs'. Stelfonta recently won a label expansion in the UK, for use in resectable mast tumours (not just inoperable ones). The story to date Qbiotics was co-founded by research scientist Dr Victoria Gordon and husband and forest ecologist Dr Paul Reddell. Both founders were employed by the Commonwealth Scientific and Industrial Research Organisation, but in 2000 Dr Gordon busted out to form Ecobiotics. The duo then formed Qbiotics in 2010. -Ecobiotics merged with Qbiotics in 2017. The pair stumbled on tigilanol tiglate when fossicking in rainforest in the Atherton Tablelands of Far North Queensland. They observed that animals spat out the seed of the blushwood tree, pointing to a non-toxic deterrent preventing the critters from eating and thus destroying the seed. Qbiotics isolated tigilanol tiglate and tests for anti-cancer activity in animals proved safe and effective. Doyle was appointed in early September 2024 after Dr Gordon stepped down, but she remains on the board. At the time, Mark Fladrich and David Phillips were appointed, while Andrew Denver and Prof Bruce Robinson stepped down. The company's chair, Dr Susan Foden died suddenly in early November and Mr Fladrich assumed the chair role. The board previously included former ASX and Cochlear chair Rick Holliday-Smith, Cochlear chief financial officer Neville Mitchell and erstwhile Macquarie Bank CEO Nicholas Moore. Taking the low road and the high road A Scottish pharmacist, Doyle has a long history with big pharma companies in medical and commercial roles. Since peregrinating to Australia at the end of 1999 on a working holiday visa, Doyle has held roles with Janssen, Novartis, Sanofi and Boehringer Ingelheim. He had lengthy stints in Paris, Singapore and Shanghai, before being poached by the smaller Aslan Pharmaceuticals (based in the Lion City). 'I liked the idea of roll up your sleeves and multi-tasking, whereas with big pharma you tend to get pigeon-holed,' he said. Doyle joined Qbiotics partly because he liked the idea of returning to Australia, notably Brisbane, but also because of the buzz of developing a drug. 'The risk of biotech is quite exciting,' he says. 'It's not for everyone. If you want a nice stable job ... get a job at Pfizer.' Soft tissue sarcoma Soft tissue sarcoma (STS) is a rare cancer that generally forms as a painless tumour in any bodily soft tissue. The company says there were 128,000 new cases of STS globally in 2023, with the incidence growing at about half a per cent per year. The US Food and Drug Administration has granted tigilanol tiglate orphan drug status for this indication. Conducted at New York's Memorial Sloan Kettering Cancer Centre, stage one of the phase IIa trial covered 10 evaluable patients with advanced STS. The study achieved an objective response rate of 80% in injected tumours, with eight patients having a complete ablation or partial ablation (reduction of 30% or more). Of the injected tumours, 22 out of 27 (81%) showed complete or partial ablation (14 complete). 'None of the 14 completely ablated tumours recurred at six months, indicating tigilanol tiglate may provide durable responses,' the company says. The trial moves to an expanded second stage, with another 40 patients targeted. Doyle says there around 80 to 120 STS sub types, but the company intends to narrow its work to the most common varieties. Head and neck cancers (HNC) Qbiotics currently is recruiting in Australia and UK for the HNC phase II trial. As with the STS trial, it is single-arm and open label. An earlier 19-patient phase I/II trial met safety and tolerability goals. Head and neck cancers are a portfolio of cancers afflicting the mouth, nose, throat, voice box, sinuses, and salivary glands. Doyle says HNCs are challenging in at least two ways. For a start, they occur close to vital organs and vessels. Secondly, patients tend to be from lower socio-economic areas. For instance, mouth cancer is quite prevalent in India and may result from chewing betel nut. Smoking and chewing tobacco and alcohol are key risk factors with mouth and voice box cancers. Oro-pharyngeal cancers are linked to the human papillomavirus. The company hopes to release top-line data later his year. Here, there and everywhere … Doyle says tigilanol tiglate is an 'interesting molecule' because it has multiple modes of action. This includes some evidence of an abscopal effect, over and above the drug's direct effect on the tumour. The abscopal effect is when localised cancer therapies lead to the shrinkage or even disappearance of tumours elsewhere in the body. Not surprisingly, the immune system is thought to transmit the tumour kill signals. In an 'off study' observation the abscopal effect was seen in a melanoma patient, in an earlier phase I 'all comers' study. (The company carried out two melanoma studies, one of them a dose-escalation effort in combo with Keytruda and the other a monotherapy). The company is carrying out exploratory work on the abscopal effect in the STS and HNC programs and hopes to present data at an upcoming congress of learned peers. In the background, the company is also undertaking a dose escalation and safety study for venous leg ulcers, which remain stubbornly hard to treat. A semi-synthetic variant, this one would be a drug rather than a device, which would be rare in wound healing. Finances and performance Qbiotics' unlisted status hasn't prevented the company from raising large wads of money: $194 million since inception, plus $60 million of tax incentives and government grants. In early 2021, the company raised a hefty $85 million, with investment firm TDM Growth Partners accounting for $50 million (existing holders took up the rest). At the end of December 2024, the company had cash of $39 million. 'We have enough money to deliver on our outlined programs, including part two of the STS trial and a venous leg ulcer study,' Doyle says. In the December half year, the company generated $1.16 million from Stelfonta sales, which 'continued to be lower than expected'. With its level of disclosure, Qbiotics' annual report looks more like the work of a listed company. With no listed mechanism – or not yet anyway – buyers and sellers can trade separately via Dr Boreham's diagnosis Doyle says Qbiotics' strategy has been to generate data in multiple tumours, including melanoma, to broaden the company's commercial appeal. 'For us it is about creating proof of concept and evidence in multiple solid tumour types, to make us attractive for partnering. 'Our sweet spot is phase II or IIb, but we need to find a big partner … with the necessary infrastructure and resources to run multiple registration studies targeting multiple solid tumour types.' He says Qbiotics is not yet at the point of having to hone its indications of interest. 'We are small nimble and get to wear multiple hats, but ultimately we are limited by resources.' In its 25th year, Qbiotics offers enough goings-on to maintain the interest of the company's circa 2,600 shareholders ahead of the listing. For the record, Grandview Research values the STS market at US$1.26 billion in 2023 and reckons the HNC sector will be worth US$5.2 billion by 2030. The vet market is estimated at US$100 million. That's decent enough, but a morsel compared to the human oncology opportunities. At a glance Qbiotics is a public unlisted company Chief executive officer: Stephen Doyle Shares on issue: 489,026,611 Financials (half year to December 31, 2024): revenue $1.16 million (up 6%), government grants $3.89 million (-4%), loss of $9.3 million (previously an $8.5 million loss), cash on hand $39.2 million (down 15%). Board: Mark Fladrich (chair), Doyle, Dr Victoria Gordon (co-founder), Dr Paul Reddell (co-founder), David Phillips, Sergio Duchini Major shareholders: TDM Growth Partners 11%, founders and staff 13%, remaining top 20 24%, remaining shareholders 52%

ABC News
an hour ago
- ABC News
Food standards regulator proposes genetically modified definition update
As food companies welcome a proposal to alter the definition of genetic modification in the Food Standards Code, organic producers fear the change could "mislead" the public. Australia's food regulator, Food Standards for Australia and New Zealand (FSANZ), has proposed a change that would allow some foods produced using gene editing techniques to avoid being labelled as genetically modified. Currently, food defined as genetically modified is subject to strict regulations and restrictions, making it difficult for food tech companies to get new products to market. Under the proposed change, food that has been gene edited would not be subject to the same rules, unless "novel DNA" has been introduced. FSANZ defines novel DNA as DNA which, as a result of the use of gene editing, is different in chemical sequence or structure. General manager of public health at FSANZ Christel Leemhuis said the definition change would "remove ambiguity" for businesses and consumers. "The new definition will … improve clarity and predictability for businesses, regulators and consumers, while continuing to protect public health and safety," Ms Leemhuis said. "[The current definition] is outdated and doesn't reflect the new technologies in the market." Ms Leemhuis said an example of what would get through under the definition change were cases where gene editing had been used to remove a gene from corn to change its starch content. "It replicates a change that can occur naturally but does it in a more targeted and efficient way," said Ms Leemhuis. Ms Leemhuis said anything with "novel DNA" would still be subject to the same standards for genetically modified food which apply now. CropLife Australia CEO Matthew Cossey said the change would bring Australian standards in line with those of global trading partners, such as the US and Canada, and open the doors for new technology. "You're not introducing a different or foreign gene, you're simply doing what we've done through traditional breeding … with no difference except in precision and time," Mr Cossey said. Croplife Australia represents innovators, developers, manufacturers, formulators and registrants of crop protection and ag-biotechnology products. Mr Cossey said Australia was lagging behind the rest of the world because the current definition made it "too difficult" to bring new products to market. "The system is antiquated and at the moment you're capturing things that just aren't [GM]," he said. "[Such as] Arctic apples and a range of other products that aren't in the Australian market." The Canadian product was developed through gene editing, to prevent browning when sliced or bruised. Mr Cossey said allergies and other health issues could also be better addressed under the change. "Things like gluten allergy could be addressed here [and] the health benefits are one of the most exciting areas in terms of the [new breeding techniques]," he said. Peak industry body Australian Organic Limited said the change would be "misleading" to the general public. Operations and technical manager Josefine Pettersson said some products created with new breeding techniques like gene editing would not require any labelling, traceability or testing prior to entering the consumer food market. Ms Pettersson said the change to the definition would mean products like purple tomatoes, which are currently being assessed by the regulator, would not need approval to go to market. "They would just be automatically approved because they are a mutation and genetic editing of the same species, tomato DNA," she said. Ms Pettersson said the group was also concerned it would not be mandatory to disclose if products had a genetically modified food in the ingredients list, but Mr Cossey rejected that. "GM foods still have mandatory labelling requirements, all GM foods will continue to have that in Australia," he said. FSANZ said consumers would still have information to ensure informed choice. Food ministers from Australia and New Zealand have until August 3 to consider FSANZ's change definition.

The Australian
an hour ago
- The Australian
Study backs Alterity tool for tracking MSA
Special Report: Alterity Therapeutics has unveiled promising new research showing its novel brain imaging tool could play a key role in diagnosing and tracking Multiple System Atrophy (MSA), a rare and aggressive neurodegenerative disease. Quality peer-reviewed publication highlights use of Alterity's MSA Atrophy Index developed to diagnose and track MSA disease progression Tool helps pinpoint changes in brain over time, making it easier to detect disease progression and assess treatments MSA Atrophy Index developed as part of Alterity's bioMUSE natural history study with Vanderbilt University Medical Center The peer-reviewed study, published in peer-reviewed journal Annals of Clinical and Translational Neurology, highlights a new MRI-based measure called the MSA Atrophy Index (MSA-AI) – developed as part of Alterity Therapeutics' (ASX:ATH) bioMUSE natural history study. Using artificial intelligence (AI), the tool helps pinpoint changes in the brain over time, making it easier to detect disease progression and assess how well treatments are working. MSA-AI offers a standardised way to measure brain shrinkage in regions affected by the disease, regardless of the subtype. This makes it a useful tool for both diagnosing patients earlier and improving how clinical trial participants are selected. The study combined data from both early-stage and more advanced MSA patients, capturing a wide range of disease severity. The approach has helped researchers confirm that the MSA-AI could reliably track changes in brain volume over time and differentiate MSA from other similar neurological conditions like Parkinson's disease and Lewy body dementia. Importantly, lower MSA-AI scores were linked to more severe symptoms and greater disease progression over 12 months, highlighting the tool's potential value in future clinical trials and patient care. About the bioMUSE study Titled Biomarkers of Progression in Multiple System Atrophy (bioMUSE), the natural history study tracks the progression of individuals with MSA, a Parkinsonian disorder without an approved therapy. The study was conducted in collaboration with Vanderbilt University Medical Center in the US under the direction of Daniel Claassen M.D, M.S, professor of neurology and principal investigator. Alterity noted that natural history studies were important for characterising disease progression in selected patient populations. Insights into early-stage MSA The company said the study had provided rich data for optimising the design of its randomised ATH434-201 phase II clinical trial and had enrolled ~20 individuals with clinically probable or clinically established MSA. The bioMUSE study continues to provide critical insights into early-stage MSA, helping select biomarkers and track disease progression in patients like those in its phase II trial. 'This research used state-of-the-art technology employed in the bioMUSE study that goes above and beyond traditional MRI methods for assessing brain volume in patients with MSA,' Alterity's US-based CEO Dr David Stamler said. 'Based on the creativity and technical skill of our colleagues at Vanderbilt University Medical Center, we now have superior tools for diagnosing MSA and tracking brain atrophy over time. 'Importantly, we observed that statistically significant reductions in brain volume over 12 months correlated with clinical worsening of the disease.' Stamler said the results underscore importance of using advanced neuroimaging methods and analytical tools in evaluating MSA, which Alterity implemented in its phase II clinical program. 'While previous MRI studies have reported brain volume reductions in MSA-affected brain regions, tracking these changes reliably has been challenging,' he said. Stamler said development of the MSA Atrophy Index can enhance the understanding of MSA progression and provide support for using brain atrophy markers for evaluation of disease-modifying therapies. 'These tools offer potential applications in diagnosis, staging, and monitoring of disease severity, contributing to more personalised care in MSA,' he said. 'We look forward to leveraging this invaluable technology for patient selection and disease progression in our phase III clinical trial.' This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.